Table 2.
Outcomes [% or mean ± standard deviation] | SPIROMICS | COPDGene | ||||
---|---|---|---|---|---|---|
Platelet Count <350 × 109/L | Platelet Count ≥350 × 109/L | p-value | Platelet Count <350 × 109/L | Platelet Count ≥350 × 109/L | p-value | |
Any Acute Exacerbation of COPD during the prior year | 30.7% | 43.6% | 0.003* | 27.5% | 37.8% | 0.02* |
Severe Acute Exacerbation of COPD during the prior year | 15.5% | 24.2% | 0.01* | 14.6% | 23.4% | 0.01* |
Modified Medical Research Council (mMRC) Questionnaire score ≥ 2 | 31.4% | 47.5% | 0.0002* | 52.9% | 64% | 0.02* |
COPD Assessment Test (CAT) score ≥ 10 | 72.4% | 86.2% | 0.001* | 66.4% | 77.5% | 0.02* |
GOLD symptom group D | 20% | 33% | 0.0009* | 19.4% | 33.3% | 0.0004* |
6-min walk distance in meters | 395 ± 128 | 352 ± 134 | 0.007a | 371 ± 124 | 358 ± 118 | 0.3a |
St. George Respiratory Questionnaire score | 38 ± 20 | 44 ± 19 | 0.0002a | 32 ± 22 | 38 ± 24 | 0.005a |
GOLD Global Initiative for Chronic Obstructive Lung Disease. *chi-squared test; at-test